251 related articles for article (PubMed ID: 35190110)
21. Treatment of impending tumor lysis with single-dose rasburicase.
Lee AC; Li CH; So KT; Chan R
Ann Pharmacother; 2003 Nov; 37(11):1614-7. PubMed ID: 14565793
[TBL] [Abstract][Full Text] [Related]
22. Treatment-naïve spontaneous tumor lysis syndrome in metastatic prostate adenocarcinoma: An unusual suspect.
Ignaszewski M; Kohlitz P
Am J Emerg Med; 2017 Sep; 35(9):1384.e1-1384.e2. PubMed ID: 28587951
[TBL] [Abstract][Full Text] [Related]
23. How to prevent and manage tumor lysis syndrome.
Held-Warmkessel J
Nursing; 2010 Feb; 40(2):26-31; quiz 31-2. PubMed ID: 20083976
[No Abstract] [Full Text] [Related]
24. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
[TBL] [Abstract][Full Text] [Related]
25. [Tumor lysis syndrome: risk factors and treatment].
Hörl WH
Wien Klin Wochenschr; 2005 Jan; 117(1-2):7-17. PubMed ID: 15986584
[TBL] [Abstract][Full Text] [Related]
26. Acute tumor lysis syndrome in a 7-month-old with hepatoblastoma.
Bercovitz RS; Greffe BS; Hunger SP
Curr Opin Pediatr; 2010 Feb; 22(1):113-6. PubMed ID: 19926992
[TBL] [Abstract][Full Text] [Related]
27. Managing malignancy-associated hyperuricemia with rasburicase.
Cheson BD; Dutcher BS
J Support Oncol; 2005; 3(2):117-24. PubMed ID: 15796443
[TBL] [Abstract][Full Text] [Related]
28. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
29. A retrospective analysis of tumor lysis syndrome management in a quaternary care hospital.
Eng S; Lee CS; Ahn S; Sharma A
J Oncol Pharm Pract; 2020 Mar; 26(2):338-344. PubMed ID: 31088218
[TBL] [Abstract][Full Text] [Related]
30. Acute tumor lysis syndrome in solid tumors--a case report and review of the literature.
Baeksgaard L; Sørensen JB
Cancer Chemother Pharmacol; 2003 Mar; 51(3):187-92. PubMed ID: 12655435
[TBL] [Abstract][Full Text] [Related]
31. Tumor lysis syndrome in induction therapy for acute myeloid leukemia before the rasburicase era.
Toda Y; Ashizawa M; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Nagayama T; Umino K; Minakata D; Morita K; Yamamoto C; Hatano K; Sato K; Fujiwara SI; Ohmine K; Kanda Y
Int J Hematol; 2024 Jun; 119(6):660-666. PubMed ID: 38575822
[TBL] [Abstract][Full Text] [Related]
32. Tumor lysis syndrome: risk factors, diagnosis, and management.
Burns RA; Topoz I; Reynolds SL
Pediatr Emerg Care; 2014 Aug; 30(8):571-6; quiz 577-9. PubMed ID: 25098804
[TBL] [Abstract][Full Text] [Related]
33. Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout.
Cammalleri L; Malaguarnera M
Int J Med Sci; 2007 Mar; 4(2):83-93. PubMed ID: 17396159
[TBL] [Abstract][Full Text] [Related]
34. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
[TBL] [Abstract][Full Text] [Related]
35. Onco-nephrology: tumor lysis syndrome.
Wilson FP; Berns JS
Clin J Am Soc Nephrol; 2012 Oct; 7(10):1730-9. PubMed ID: 22879434
[TBL] [Abstract][Full Text] [Related]
36. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
[TBL] [Abstract][Full Text] [Related]
37. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
[TBL] [Abstract][Full Text] [Related]
38. Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.
Alakel N; Middeke JM; Schetelig J; Bornhäuser M
Onco Targets Ther; 2017; 10():597-605. PubMed ID: 28203093
[TBL] [Abstract][Full Text] [Related]
39. Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients.
Herrington JD; Dinh BC
J Oncol Pharm Pract; 2015 Apr; 21(2):111-7. PubMed ID: 24549060
[TBL] [Abstract][Full Text] [Related]
40. [Tumor lysis syndrome].
Hagino T
Gan To Kagaku Ryoho; 2010 Jun; 37(6):984-8. PubMed ID: 20567098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
